<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="family-medicine" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">381</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2025.50101</article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Family Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Efficacy and Safety of Oral Semaglutide (Rybelsus) for Weight Reduction in Individuals with Obesity and Type 2 Diabetes: A Systematic Review
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ibrahem</surname>
<given-names>Azhar M. Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ismail</surname>
<given-names>Fatimah M. Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AlAbd</surname>
<given-names>Fatimah M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsubaie</surname>
<given-names>Huda I.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghazal</surname>
<given-names>Zainab A. Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alkadi</surname>
<given-names>Fatimah A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AlOmar</surname>
<given-names>Fatimah E.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alahmed</surname>
<given-names>Alzahra A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>jasim</surname>
<given-names>Budur I. Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alkhalifah</surname>
<given-names>Aqilah R.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsaleem</surname>
<given-names>Maryam A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Albrahim</surname>
<given-names>Fatimah M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alkhars</surname>
<given-names>Fatimah A.</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>6</day>
<month>01</month>
<year>2025</year>
</pub-date>
<volume>5</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>12</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Obesity remains a significant global health issue, increasing the risk of chronic conditions such as diabetes, cardiovascular disease, and certain cancers. Despite the importance of lifestyle interventions, many individuals with obesity require pharmacological support for effective weight management. Oral semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise due to its ease of oral administration. This systematic review, registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, evaluated published randomized controlled trials (RCTs). A total of 9 RCTs, published between 2017 and 2020, were selected from an initial pool of 1,089 studies found through PubMed, the Cochrane Database of Systematic Reviews (Cochrane), Web of Science, and the Medical Literature Analysis and Retrieval System Online (MEDLINE). The findings indicate that oral semaglutide significantly reduces body weight, improves glycemic control, enhances satiety, and lowers energy intake compared to placebos and alternative treatments. However, long-term use was associated with a higher incidence of side effects. Overall, oral semaglutide is an effective treatment for obesity, providing significant weight loss and glycemic control. Its convenience as an oral option makes it favorable compared to injectable GLP-1 receptor agonists, though long-term use may warrant monitoring for cost and gastrointestinal side effects.
</p>
</abstract>
<kwd-group>
<kwd>Oral semaglutide</kwd>
<kwd> Obesity</kwd>
<kwd> Weight reduction</kwd>
<kwd> GLP-1 receptor agonist</kwd>
<kwd> Glycemic control</kwd>
</kwd-group>
</article-meta>
</front>
</article>